ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novartis and Jemincare side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovartisJemincare
studies on the registry3,90037
open to participants now21230
phase 3 studies under way943
reach primary completion within a year1256
programswith a study of their own in two years77+7 named only9

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovartisJemincare
Phase 1

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%

Jemincare: 5 of its 9 programs at phase 1

  1. JMKX000197phase 1
  2. JMKX003948phase 1
  3. Amiodaronephase 1
  4. JMKX005425phase 1
  5. JY1001phase 1
56%
Phase 2

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
00%
Phase 3

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%

Jemincare: 3 of its 9 programs at phase 3

  1. JMKX003142phase 3
  2. ozureprubartphase 3
  3. KRAS G12C Inhibitor JMKX001899phase 3
33%
Approved, new studies

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Jemincare: 1 of its 9 programs at approved, new studies

  1. sonidegibapproved, new study
11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · Jan 4 · NCT05397496
  2. opnurasibphase 3 · Jan 25 · NCT04699188
  3. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 2 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Jemincare3 readouts · 1 phase 3···

Jemincare, Feb ’27: 1 program whose next study reaches primary completion

  1. JMKX003142phase 3 · Feb 28 · NCT06800651
··

Jemincare, May ’27: 1 program whose next study reaches primary completion

  1. JY1001phase 1 · May 0 · NCT07848945

Jemincare, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ozureprubartphase 3 · Jun 7 · NCT07402213
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 5

Jemincare

New programs 1

  • JY1001phase 1 · first study · Sep 17 · Pain

Reached a new phase 1

  • JMKX003142phase 3 · Sep 7 · Polycystic Kidney, Autosomal Dominant

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionNovartisJemincare
Breast Neoplasmsboth · compare here

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Jemincare in Breast Neoplasms: 1 program

  1. sonidegibapproved, new study

Their studies: Jemincare’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Jemincare in Carcinoma, Non-Small-Cell Lung: 1 program

  1. KRAS G12C Inhibitor JMKX001899phase 3

Their studies: Jemincare’s studies of Carcinoma, Non-Small-Cell Lung in search

Atrial Fibrillationboth · compare here

Novartis in Atrial Fibrillation: 2 programs

  1. abelacimabphase 3
  2. PKN605phase 2

Their studies: Novartis’s studies of Atrial Fibrillation in search

Jemincare in Atrial Fibrillation: 1 program

  1. Amiodaronephase 1

Their studies: Jemincare’s studies of Atrial Fibrillation in search

Polycystic Kidney, Autosomal Dominantboth · compare here

Novartis in Polycystic Kidney, Autosomal Dominant: 1 program

  1. farabursenphase 1

Their studies: Novartis’s studies of Polycystic Kidney, Autosomal Dominant in search

Jemincare in Polycystic Kidney, Autosomal Dominant: 2 programs

  1. JMKX003142phase 3
  2. Amiodaronephase 1

Their studies: Jemincare’s studies of Polycystic Kidney, Autosomal Dominant in search

Carcinoma, Renal Cellboth · compare here

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Jemincare in Carcinoma, Renal Cell: 1 program

  1. JMKX003948phase 1

Their studies: Jemincare’s studies of Carcinoma, Renal Cell in search

Chronic Urticariaboth · compare here

Novartis in Chronic Urticaria: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Chronic Urticaria in search

Jemincare in Chronic Urticaria: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Chronic Urticaria in search

Heart Failureboth · compare here

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Jemincare in Heart Failure: 1 program

  1. JMKX003142phase 3

Their studies: Jemincare’s studies of Heart Failure in search

Macular Degenerationboth · compare here

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

Jemincare in Macular Degeneration: 1 program

  1. JMKX003948phase 1

Their studies: Jemincare’s studies of Macular Degeneration in search

Pancreatic Neoplasmsboth · compare here

Novartis in Pancreatic Neoplasms: 1 program

  1. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Pancreatic Neoplasms in search

Jemincare in Pancreatic Neoplasms: 1 program

  1. sonidegibapproved, new study

Their studies: Jemincare’s studies of Pancreatic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetNovartisJemincare
KRASopnurasibruleKRAS G12C Inhibitor JMKX001899rule
A target, or a pathogen for a vaccine, known for: Novartis 56 of 77 · Jemincare 4 of 9 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).